Khiron Life Sciences Corp.
KHRNH.V
TSX
| 09/30/2022 | 06/30/2022 | ||||
|---|---|---|---|---|---|
| Revenue | -25.96% | -4.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -25.96% | -4.42% | |||
| Cost of Revenue | -20.07% | -33.18% | |||
| Gross Profit | -31.27% | 56.16% | |||
| SG&A Expenses | -0.38% | -19.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.21% | -22.08% | |||
| Operating Income | -9.94% | 38.40% | |||
| Income Before Tax | -53.05% | 59.60% | |||
| Income Tax Expenses | 449.64% | -482.98% | |||
| Earnings from Continuing Operations | -61.16% | 60.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -61.16% | 60.20% | |||
| EBIT | -9.94% | 38.40% | |||
| EBITDA | -14.65% | 42.04% | |||
| EPS Basic | -40.66% | 61.76% | |||
| Normalized Basic EPS | -29.31% | 61.07% | |||
| EPS Diluted | -68.13% | 61.76% | |||
| Normalized Diluted EPS | -29.31% | 61.07% | |||
| Average Basic Shares Outstanding | 15.06% | 3.93% | |||
| Average Diluted Shares Outstanding | 15.06% | 3.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
